Indian pharma sells generics to America, vaccines to the world and branded drugs at home. The money sits in three layers: formulations (Sun, Cipla, Lupin - high margin, USFDA-sensitive), APIs and CRDMO (Divi's - China's-plus-one beneficiary) and domestic brands (steady, price-controlled).
One regulatory letter can halve a stock, so screening here means reading USFDA inspection history, US revenue share and ANDA pipelines - not just P/E ratios.
Stocks in this collection
Prices move every second, so instead of a stale price table, here is the membership list with why each stock belongs. Add them to a watchlist to see live prices, sparklines and P/E ratios.
| Ticker | Exchange | Company | Why it belongs |
|---|---|---|---|
| SUNPHARMA | NSE / BSE | Sun Pharmaceutical | Specialty pivot (Ilumya, Winlevi); watch specialty ramp versus generic drag. |
| CIPLA | NSE / BSE | Cipla | Respiratory franchise plus US generics; watch USFDA plant status. |
| DRREDDY | NSE / BSE | Dr Reddy's | US generics plus Revlimid-type opportunities; watchExcluded-product cliffs. |
| DIVISLAB | NSE / BSE | Divi's Laboratories | API/CRDMO leader; watch custom-synthesis growth and China-plus-one share gains. |
| LUPIN | NSE / BSE | Lupin | US + India mix; watch facility remediation and complex-generic launches. |
| AUROPHARMA | NSE / BSE | Aurobindo Pharma | Volume generics plus injectables; watch Eugia demerger value unlocking. |
How to screen pharma stocks yourself
- Clean USFDA record (no OAI/Warning Letter on key plants) - check the FDA database, not just management commentary.
- US revenue under 40% or diversified - concentration plus price erosion is the classic double blow.
- ANDA pipeline with limited-competition launches - plain-vanilla generics erode 10–20% yearly on price.
- Domestic growth above IPM average - India business stability funds US volatility.
- Net cash or minimal debt - regulatory shocks hurt less when the balance sheet is clean.
Risks to watch
- Single-plant dependence. If one facility makes 40% of US revenue, one Form 483 can define your year.
- Ignoring price erosion. US generic prices fall most years - volume growth must outrun it.
- Paying specialty multiples for generic earnings. Reserve premium P/Es for proven specialty or CRDMO franchises.
Frequently asked questions
Why do pharma stocks crash on USFDA news?
America is the profit pool. An import alert or warning letter can block a plant's US sales overnight - revenue, margins and multiples all reset together.
Sun Pharma vs Divi's - which is better?
Different sports: Sun is a specialty-formulations compounder, Divi's an API/CRDMO margin machine. Own the exposure you understand, or split across both layers.
What is an ANDA?
Abbreviated New Drug Application - the US approval that lets a generic maker sell a copy of a branded drug. Pending ANDAs are the visible pipeline; approvals are the revenue events.
Track it live
Add every stock below to a Ticker Screener watchlist and the ticker tape follows them across every site you browse, with price alerts when your levels hit.
One-click import, switchable P/E / ROCE / ROE columns, Smart Focus on big moves, and background price alerts.
Keep exploring
IT stocks in India
IT stocks in India - TCS, Infosys, HCL Tech, Persistent and more - deal wins, attrition and margin screens, US-recession risks, FAQs.
EV stocks in India
EV stocks in India - Tata Motors, Mahindra, Ola Electric, Exide, Tata Power and more - penetration metrics, battery screens, risks, FAQs.
Defence stocks in India
Defence stocks in India - HAL, BEL, Mazagon Dock, Cochin Shipyard and more - with screening criteria, order-book metrics, risks and FAQs.
P/E Ratio
Price-to-earnings: what you pay for each rupee or dollar of yearly profit. The starting lens for cheap vs expensive.
ROE
Return on equity: profit earned per rupee of shareholder money. High and stable ROE compounds wealth.
Market Cap
Price times shares outstanding: the market's price tag for the whole company. Defines large, mid and small caps.
52-Week High / Low
A stock's highest and lowest price over the past year. Breakouts signal strength; breakdowns signal trouble - both demand volume proof.
US Tariffs & the China+1 Play: Winners and Losers for Indian Equities
US-India tariff cut to 18%, 60% of US smartphones now India-sourced. A 4-box filter - tariff gap, certified capacity, value-add, stickiness - to separate real beneficiaries from story stocks.
From Crude to Phenol: How Global Commodity Cycles Hit Indian Margins
Phenol Rs 85 to Rs 160, melamine Rs 88 to Rs 135, then relief after shipping lanes reopened. The Brent-to-laminate chain and the spread tracker for Building Materials EBITDA.
For education only, not financial advice. Membership lists change with corporate actions and index reviews — verify tickers before investing.